NIKKEI 225
39,103.22 +486.12 (+1.26%) HANG SENG
18,868.71 -326.89 (-1.70%) CRUDE OIL
76.82 -0.75 (-0.97%) GOLD FUTURES
2,335.90 -57.00 (-2.38%) DOW
39,058.21 -612.83 (-1.54%) Bitcoin GBP
53,009.44 -1,844.97 (-3.36%)
AGEN Jun 2024 7.000 call
| Previous close | 4.5000 |
| Open | 4.4000 |
| Bid | 4.7000 |
| Ask | 5.7000 |
| Strike | 7.00 |
| Expiry date | 2024-06-21 |
| Day's range | 4.4000 - 4.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Business Wire
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
LEXINGTON, Mass., May 23, 2024--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial Officer, will participate in a fireside chat and investor one-on-ones at the upcoming Goldman Sachs Global Healthcare Conference on June 10th – 13th in Miami Beach, Florida. The fireside chat will take place at 8:00 a.m. ET on June 12th.
- Business Wire
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
LEXINGTON, Mass., May 16, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensilimab plus balstilimab (BOT/BAL) combination therapy studies in patients with relapsed/refractory metastatic colorectal cancer that is not MSI-high or dMMR (r/r MSS mCRC), as well as the
Insider MonkeyAgenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript
Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript May 7, 2024 Agenus Inc. beats earnings expectations. Reported EPS is $-3.04104, expectations were $-3.1. AGEN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by, and welcome to […]
